Abstract:Cutaneous melanoma is a highly aggressive cancer capable of distant and lethal metastatic spread. Recent breakthroughs have come from understanding oncogenic signaling and cancer immunobiology. Targeted therapies successfully block MAPK signaling in BRAFV600e mutant melanoma with remarkably high clinical responses followed by rapid relapse, whereas checkpoint inhibitors activating the immune response induce long-lasting responses, albeit only in a subset of patients. These limitations have driven interest in understanding innate and acquired resistance. Using an immunocompetent genetically-engineered mouse model of BRAF-driven melanoma, which phenocopies the human disease in its development, histopathology, and response to therapy, we focused on the tumor microenvironment (TME), seeking to elucidate resistance mechanisms. Our investigations have revealed that tumor-associated macrophages (TAMs) are a critical component of the TME, predominantly polarized toward a pro-tumoral "M2-like" phenotype, producing immunosuppressive factors and exhibiting extensive immuno-suppressive capabilities suggesting that they might significantly hinder immune responses in the melanoma TME. Seeking to assess their functional importance, we have found that combining conventional strategies with TAMs-reprogramming agents stimulates anti-tumor immune responses, leading to improved survival and responsiveness to standard-of-care therapies. These data highlight the central role played by macrophages in melanoma progression and demonstrate that pharmacologic reprogramming of macrophages represents a new therapeutic modality with the potential to elicit more effective anti-tumor immune responses against this devastating disease. Citation Format: Melanie Tichet, Agnieszka Chryplewicz, Douglas Hanahan. Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr B41.

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment

Targeted Delivery of Oligonucleotides into Tumor-Associated Macrophages for Cancer Immunotherapy

Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype

Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms

Targeting Tumor-Associated Macrophages with the Immune-Activating Nanomedicine for Achieving Strong Antitumor Activity with Rapid Clearance from the Body

Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival

Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy

Nanoengineered drug delivery in cancer immunotherapy for overcoming immunosuppressive tumor microenvironment

Macrophage-modulating nanomedicine for cancer immunotherapy

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Engineered Bacterial Outer Membrane Vesicles as Controllable Two‐way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells